Brief: Scynexis Q2 EPS USD -0.3
08/08/2024 21:30
Aug 08 (Reuters) - Scynexis Q2 product revenue USD 736 thousand. * Q2 pretax profit USD -14.458 million * Q2 operating expenses USD 9.973 million * Q2 basic EPS USD -0.3 * Q2 net income USD -14.458 million
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview